Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on August 29, 2018, covering events occurring on August 28, 2018. The filing primarily addresses the appointment of a new Chief Financial Officer and the departure of the previous principal financial officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the leadership transition in the finance department:
- Appointment: Robert E. Gagnon was appointed Chief Financial Officer (CFO) effective August 28, 2018.
- Departure: Dan Paterson ceased serving as the principal financial officer and principal accounting officer, though he will continue as Chief Operating Officer.
Management Commentary, Risks, and Unusual Items
The filing details the compensatory arrangements for the new CFO, Robert E. Gagnon, under an indefinite-term employment agreement:
- Base Salary: $380,000 annually.
- Annual Bonus: Target of 40% of base salary.
- Sign-on Bonus: One-time payment of $40,000, expected to be paid on or about September 14, 2018.
- Stock Options: Grant of 450,000 options at an exercise price of $9.43 per share.
- 350,000 shares vest over time (25% at one year, then quarterly).
- 100,000 shares vest upon achieving $150 million in net sales of duvelisib within 24 months of the first commercial sale.
- Restricted Stock Units (RSUs): Grant of 50,000 RSUs vesting on the first anniversary of the grant date.
- Severance: Provisions for severance payments exist if employment is terminated without Cause or if the officer resigns for Good Reason, subject to a release of claims.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the vesting schedule and performance metrics for the 100,000 performance-based stock options tied to duvelisib sales.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Monitor future filings for the impact of the new CFO on financial reporting and capital strategy.